HIV Treatment Strategies – The role of integrase strand transfer inhibitors
HIV behandelstrategieën – de rol van integraseremmers
The studies that will be described in Chapter 2 to 8, and which resulted in this thesis, aim to evaluate the effectiveness and safety of new HIV treatment strategies with INSTIs, especially DTG, in HIV-1 infected individuals. Furthermore, several aspects of cART-toxicity with dual NRTI backbones in combination with an INSTI, PI, or NNRTI are evaluated. The ultimate goal is a more individualized and patient-centered therapy by balancing virological and immunological efficacy with reduction of the risk of adverse events.
This thesis focuses on three issues.
Part 1 focuses on the effects of a switch from triple cART to DTG as maintenance monotherapy.
In part 2 the safety of initiating INSTI-containing cART in HIV late presenters with compromised immunity on the risk of IRIS is discussed.
Part 3 concentrates on aspects regarding safety of the NRTI backbone in INSTI, PI, or NNRTI containing cART and possibilities to further individualize HIV treatment.
|A. Verbon (Annelies) , B.J.A. Rijnders (Bart) , C. Rokx (Casper)|
|Erasmus University Rotterdam|
|Organisation||Department of Medical Microbiology and Infectious Diseases|
Wijting, I.E.A. (2019, January 8). HIV Treatment Strategies – The role of integrase strand transfer inhibitors. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/112830
|Stellingen-Ingeborg-Wijting.pdf , 154kb|
|112830_Chapter_1-General_introduction_and_outline_of_the.pdf Final Version , 1mb|
|112830_Chapter_2-Dolutegravir_as_maintenance_monotherapy.pdf Final Version , 566kb|
|112830_Chapter_3-HIV-1_resistance_dynamics_in_patients_wi.pdf Final Version , 1mb|
|112830_Chapter_4-Predictors_of_virological_failure_in_HIV.pdf Final Version , 416kb|
|112830_Chapter_5-Changes_in_renal-_bone-_lipid-_and_infla.pdf Final Version , 547kb|
|112830_Chapter_6-Immune_reconstitution_inflammatory_syndr.pdf Final Version , 1mb|
|112830_Chapter_7-Inosine_5_-triphosphatase_activity_is_as.pdf Final Version , 408kb|
|112830_Chapter_8-Switching_to_tenofovir_alafenamide_fumar.pdf Final Version , 459kb|
|112830_Chapter_9-Summarizing_discussion.pdf Final Version , 406kb|
|112830_Chapter_10-Nederlandse_samenvatting.pdf Final Version , 279kb|
|112830_Chapter_11-Publications_PhD_portfolio_Curriculum_V.pdf Final Version , 373kb|